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1. INTRODUCTION {#jia225489-sec-0005}
===============

Several antiretroviral drugs are being considered for use in the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2). Protease inhibitors have been considered as candidate therapy because they inhibit enzymes that activate envelope glycoproteins as part of the process of viral entry into cells \[[1](#jia225489-bib-0001){ref-type="ref"}\]. The use of lopinavir/ritonavir (LPV/r) has been supported by data from in vitro studies, animal models and positive clinical outcomes when LPV/r was given to patients infected with severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) diseases also caused by coronaviruses \[[2](#jia225489-bib-0002){ref-type="ref"}, [3](#jia225489-bib-0003){ref-type="ref"}, [4](#jia225489-bib-0004){ref-type="ref"}, [5](#jia225489-bib-0005){ref-type="ref"}\]. Other antiretrovirals have been proposed based on virtual screening and in vitro studies, and several clinical trials are planned. Lopinavir/ritonavir (LPV/r) is included in rapid guidance issued by researchers from Wuhan University based on clinical use during prior epidemics of severe acute respiratory syndrome (SARS) and MERS coronavirus (CoV) infections \[[6](#jia225489-bib-0006){ref-type="ref"}\].

This systematic review summarizes the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.

2. METHODS {#jia225489-sec-0006}
==========

Based on in vitro activity, molecular docking studies, or reported use in prior reviews the following drugs were screened \[[7](#jia225489-bib-0007){ref-type="ref"}, [8](#jia225489-bib-0008){ref-type="ref"}, [9](#jia225489-bib-0009){ref-type="ref"}, [10](#jia225489-bib-0010){ref-type="ref"}, [11](#jia225489-bib-0011){ref-type="ref"}\]: lopinavir/ritonavir, emtricitabine, tenofovir, atazanavir, ritonavir, darunavir, nelfinavir, indinavir, saquinavir, lamivudine and zidovudine (Search strategy provided in Appendix [S1](#jia225489-sup-0001){ref-type="supplementary-material"}).

Three databases -- Medline via PubMed, EMBASE and the Cochrane Library -- were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID‐19 treated with antiretrovirals; studies using antiretrovirals for the prevention of these infections were also sought. The WHO database of publications on COVID‐19 was also searched <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov>.

Any study design that reported clinical outcome data was included, and there were no language restrictions. Clinicaitrials.gov and Chictr.org.cn were searched for ongoing and completed trials. Data are summarized per study, but not pooled in meta‐analysis due to the limited number of studies reporting outcomes for each disease. The review was conducted by a single reviewer (NF), with data extraction validated by a second reviewer (AR). The quality (or certainty) of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach \[[12](#jia225489-bib-0012){ref-type="ref"}\].

3. RESULTS AND DISCUSSION {#jia225489-sec-0007}
=========================

3.1. Antiretroviral drugs for treatment {#jia225489-sec-0008}
---------------------------------------

From an initial screen of 433 titles, two randomized controlled trials and 21 observational studies provided clinical outcome data on the use of antiretroviral drugs for treatment, and 3 studies reported outcomes for prevention. Three studies were excluded: one because cause of infection was unclear \[[13](#jia225489-bib-0013){ref-type="ref"}\], one because the original study was retracted during the conduct of this systematic review \[[14](#jia225489-bib-0014){ref-type="ref"}\] and one because lamivudine was given to control chronic hepatitis B infection and its use could not be linked to SARS outcomes \[[15](#jia225489-bib-0015){ref-type="ref"}\]. Among the included studies, the majority reported outcomes using LPV/r as treatment; two two studies reported outcomes among HIV‐positive individuals who were on a combination antiretroviral drugs for management of HIV \[[16](#jia225489-bib-0016){ref-type="ref"}, [17](#jia225489-bib-0017){ref-type="ref"}\].

Characteristics of included studies and patient outcomes are summarized in Table [1](#jia225489-tbl-0001){ref-type="table"}.

###### 

Clinical studies evaluating LPV/r for MERS, SARS and Covid‐19

+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Author                                                                                                | Population                                                                                   | Intervention                                                                                                                                             | Co‐interventions                                                                                                                                                                                     | Timing/duration of therapy                                                                | Comparitor                                             | Mortality                                                  | Details                                                                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Country                                                                                               | Study design                                                                                 |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+=======================================================================================================+==============================================================================================+==========================================================================================================================================================+======================================================================================================================================================================================================+===========================================================================================+========================================================+============================================================+=====================================================================================================================================================================+
| Treatment                                                                                             |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| SARS                                                                                                  |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Chan 2003 \[[2](#jia225489-bib-0002){ref-type="ref"}\]                                                | 75 adults                                                                                    | LPV/r 400/100 Q12H + standard treatment protocol                                                                                                         | Ribavarin either as cotreatment with LPV/r or as rescue therapy, pulse Methylprednisone 3 mg/kg/day or tailing hydrocortisone therapy 21 days 100 to 200 mg/day + mechanical ventilation if required | 10 to 14 days depending on severity                                                       | 977 matched controls from hospital data                | LPV/r: 5/75 died                                           | Reduction in mortality: 2.3% (0% to 6.8%) vs. 15.6% (9.8% to 22.8%)                                                                                                 |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Matched cohort study                                                                         |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Control: 147/977 died                                      | Reduction in intubation rate: 0% vs 11% (7.7% to 15.3%)                                                                                                             |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Chu 2004 \[[18](#jia225489-bib-0018){ref-type="ref"}\]                                                | 41 adults                                                                                    | LPV/r 400/100 Q12H as initial therapy (n = 12), time of onset of symptoms 3.5 days. For rescue treatment (n = 29) time of onset of symptoms 14 days      | Ribavarin and IV steroids                                                                                                                                                                            | 14 days                                                                                   | 111 historical controls                                | LPV/r: 0/41 died                                           | Treatment group: 21‐day mortality/ARDS: 0/41, ARDS/death before 21 days: 1/44; Historical controls: 21 day mortality/ARDS: 7/111, ARDS/death before 21 days: 32/111 |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Case‐control study with historical controls                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Control: 7/111 died                                        |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Wong 2004 \[[17](#jia225489-bib-0017){ref-type="ref"}\]                                               | 30‐year‐old man                                                                              | Abacavir 300 mg Q12H, efavirenz 600 mg once daily, TDF 300 mg Q12H, LPV/r                                                                                | Ribavirin                                                                                                                                                                                            | ARVs provided for HIV treatment                                                           | n/a                                                    | 0/1 died                                                   | Recovered                                                                                                                                                           |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Case report                                                                                  | 4 x 133.3 mg/33.3 mg                                                                                                                                     | 1200 mg three times a day and prednisolone 25 mg                                                                                                                                                     |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          | three times a day                                                                                                                                                                                    |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          | 3TC (for hepatitis flare)                                                                                                                                                                            |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MERS                                                                                                  |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Spanakis 2014 \[[19](#jia225489-bib-0019){ref-type="ref"}\]                                           | 69‐year‐old man                                                                              | LPV/r 400/100 Q12H                                                                                                                                       | peg‐interferon 180 mcg 1/wk for 12 days, RBV, empirical antibiotics                                                                                                                                  | 2 months and 6 days; RBV d/c on day 20                                                    | n/a                                                    | LPV/r: 1/1 died                                            | Died due to Septic Shock + MODS; incidental diagnosis of adenocarcinoma colon                                                                                       |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Greece                                                                                                | Case report                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Meyer 2015 \[[20](#jia225489-bib-0020){ref-type="ref"}\]                                              | 29‐year‐old woman                                                                            | LPV/r                                                                                                                                                    | Supportive intensive care therapy                                                                                                                                                                    | nr                                                                                        | n/a                                                    | LPV/r                                                      | Complete clinical recovery                                                                                                                                          |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Austria                                                                                               | Case report                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | 0/1 died                                                   |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Shalhoub 2015 \[[16](#jia225489-bib-0016){ref-type="ref"}\]                                           | 51‐year‐old man                                                                              | TDF/FTC 300/200 mg once daily + ATV/r 300 mg/100 mg) once daily                                                                                          | Supportive intensive care therapy                                                                                                                                                                    | ARVs initiated for HIV treatment                                                          | n/a                                                    | 0/1 died                                                   | Recovered                                                                                                                                                           |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Saudi Arabia                                                                                          | Case report                                                                                  |                                                                                                                                                          | IFN 2a 180 mcg 1/wk, RBV (loading dose of 2 gm, followed by 600 mg orally every 12 hours)                                                                                                            |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          | Treatment for CMV                                                                                                                                                                                    |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          | prophylactic trimethoprim/sulfamethoxazole 960 mg daily                                                                                                                                              |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Kim 2016 \[[22](#jia225489-bib-0022){ref-type="ref"}\]                                                | 64‐year‐old man                                                                              | LPV/r 400/100 Q12H                                                                                                                                       | Ribavarin 2 g LD, 1.2 g TID, IFN 2alpha 180 mcg/0.5 mL from day 4 of admission, Empirical therapy with piperacillin/tazobactam and azithromycin from Day 1 of admission                              | 7 days                                                                                    | n/a                                                    | LPV/r: 0/1 died                                            | Discharged on day 13 due to clinical improvement                                                                                                                    |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Rep Korea                                                                                             | Case Report                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Choi 2016 \[[3](#jia225489-bib-0003){ref-type="ref"}\]                                                | 120 adults                                                                                   | 138 patients received antivirals among whom 120 received                                                                                                 | Antibiotics, haemodialysis, ECMO and convalescent sera. \>80% of patients given LPV/r also received IFN                                                                                              | Median time from onset of illness to treatment was 6 days                                 | n/a                                                    | LPV/r: 24/120 died                                         | Median interval from symptom onset to death was 14 days                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Rep Korea                                                                                             | Retrospective observational study                                                            | LPV/r‐containing regimens                                                                                                                                |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Alhumaid 2018 \[[21](#jia225489-bib-0021){ref-type="ref"}\][^a^](#jia225489-note-0003){ref-type="fn"} | 41 patients                                                                                  | 41 patients received LPV/r                                                                                                                               | IFN, RBV and antibiotics                                                                                                                                                                             | nr                                                                                        | n/a                                                    | LPV/r                                                      |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Saudi Arabia                                                                                          | Retrospective observational study                                                            |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | 17/41 died                                                 |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| COVID‐19                                                                                              |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Cao 2020 \[[23](#jia225489-bib-0023){ref-type="ref"}\]                                                | 199 patients                                                                                 | 100 adult patients received LPV/r 400/100 Q12H                                                                                                           | Supportive care                                                                                                                                                                                      | 14 days                                                                                   | Supportive care alone                                  | LPV/r                                                      | LPV/r not associated with a statistically significant difference in time                                                                                            |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Randomized trial                                                                             |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | 14/99 died                                                 | to clinical improvement                                                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Control                                                    |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | 25/100                                                     |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Li 2020 \[[24](#jia225489-bib-0024){ref-type="ref"}\]                                                 | 21 adult patients received LPV/r                                                             | LPV/r 200/500 Q12H                                                                                                                                       | Some patients received gama globulin.                                                                                                                                                                | 7 to 14 days                                                                              | 16 received arbidol                                    | LPV/r                                                      | Mild/moderate cases enrolloed.                                                                                                                                      |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Randomized trial                                                                             |                                                                                                                                                          | All patients received supportive care and oxygen therapy if needed                                                                                                                                   |                                                                                           | 7 received no antivirals                               | 0/21 died                                                  | More patients treated with LPV/r progressed to severe/critical status                                                                                               |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Wang 2020 \[[28](#jia225489-bib-0028){ref-type="ref"}\]                                               | 4 adult patients                                                                             | LPV/r 400/100 Q12H                                                                                                                                       | Umifenovir (Arbidol), SFJDC                                                                                                                                                                          | 6 to 15 days                                                                              | n/a                                                    | LPV/r: 0/3 died                                            | Outcome of 1 patient unknown                                                                                                                                        |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Case series                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Lim 2020 \[[25](#jia225489-bib-0025){ref-type="ref"}\]                                                | 54‐year‐old man                                                                              | LPV/r 400/100 Q12H from day 8 of admission, day 10 from onset of symptoms                                                                                | Other treatments included: Azithromycin, ceftriaxone, levofloxacin/                                                                                                                                  | 10 days                                                                                   | n/a                                                    | LPV/r: 0/1 died                                            | Patients showed clinical improvement following initiation with LPV/r                                                                                                |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Rep Korea                                                                                             | Case report                                                                                  |                                                                                                                                                          | Tazobactam and 1 dose of Peramivir                                                                                                                                                                   |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Han 2020 \[[26](#jia225489-bib-0026){ref-type="ref"}\]                                                | 47‐year‐old man                                                                              | LPV/r 400/100 daily on day 4 of illness                                                                                                                  | Methylprednisolone (40 mg daily), IFN alfa‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) and moxifloxacin hydrochloride (0.4 g daily                                                | Unclear, but discharged after 10 days                                                     | n/a                                                    | LPV/r: 0/1 died                                            | Patient received LPV/r and was discharged on day 10.                                                                                                                |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Case report                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Kim 2020 \[[27](#jia225489-bib-0027){ref-type="ref"}\]                                                | 35‐year‐old woman                                                                            | LPV/r 800/200 daily                                                                                                                                      | Oxygen supplementation                                                                                                                                                                               | Unclear but fever persisted for 10 days                                                   | n/a                                                    | LPV/r: 0/1 died                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Rep Korea                                                                                             | Case report                                                                                  |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Young 2020 \[[29](#jia225489-bib-0029){ref-type="ref"}\]                                              | 5 adults                                                                                     | 5 patients treated with LPV/r (200 mg/100 mg Q12H for up to 14 days)                                                                                     | Oxygen supplementation                                                                                                                                                                               | within 1 to 3 days of desaturation                                                        | n/a                                                    | LPV/r: 0/5 died                                            | 4/5 patients developed nausea, vomiting, and/or diarrhoea, and 3 developed                                                                                          |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Singapore                                                                                             | Retrospective cohort                                                                         |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | 3/5 improved 2/5 developed progressive respiratory failure | Abnormal liver function test results.                                                                                                                               |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            | Only 1 completed the full 14‐day treatment course                                                                                                                   |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Chen 2020 \[[31](#jia225489-bib-0031){ref-type="ref"}\]                                               | 99 patients, of which 75 received LPV/r                                                      | LPV/r 500 mg Q12H                                                                                                                                        | oseltamivir (75 mg every 12 hours, orally), ganciclovir (0·25 g every 12 hpurs, intravenously).                                                                                                      | 3 to 14 days                                                                              | n/a                                                    | 2/75 died                                                  | 57 remained in hospital                                                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          | Antibiotics                                                                                                                                                                                          |                                                                                           |                                                        |                                                            | 31 discharged                                                                                                                                                       |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            | 11 died                                                                                                                                                             |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Jun 2020 \[[32](#jia225489-bib-0032){ref-type="ref"}\]                                                | 52 patients received LPV/r                                                                   | LPV/r Q12H for 5 days                                                                                                                                    | IFN alpha‐2b and supportive care                                                                                                                                                                     |                                                                                           | ArdiboL: 34 patients                                   | LPV/r: 0/52                                                | No reported deaths                                                                                                                                                  |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           | No antivirals: 48 patients                             |                                                            | LPV/r: 2/52 severe                                                                                                                                                  |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            | Abidol: 1/33                                                                                                                                                        |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            | Control: 2/48                                                                                                                                                       |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Liu 2020 \[[30](#jia225489-bib-0030){ref-type="ref"}\]                                                | 10 patients received LPV/r                                                                   | LPV/r 400/100 Q12H                                                                                                                                       | Oxygen supplementation.                                                                                                                                                                              | 5 days from onset of symptoms                                                             | n/a                                                    | LPV/r: 0/10                                                |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          | I patient also received TDF for underlying liver disease. 9/10 also received IFN alpha‐2b                                                                                                            |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Deng 2020 \[[33](#jia225489-bib-0033){ref-type="ref"}\]                                               | 33 patients received LPV/r                                                                   | LPV/r 400/100 Q12H                                                                                                                                       | Some patients received corticosteroids                                                                                                                                                               | 5 to 21 days                                                                              | 16/33 patients also received arbidol                   | LPV/r: 0/17                                                | After 14 days, coronavirus no longer detected by PCR                                                                                                                |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          | Supportive care                                                                                                                                                                                      |                                                                                           |                                                        | LPV/r/arbidol: 0/16                                        |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Liu 2020Liu 2020 \[[34](#jia225489-bib-0034){ref-type="ref"}\]                                        | 56 patients, of which 53 patients received LPV/r                                             | LPV/r 400/100 Q12H                                                                                                                                       | Some patients received IFH & traditional Chinese medicines                                                                                                                                           |                                                                                           | n/a                                                    | 3/56                                                       | Outcomes not linked to receipt of LPV/r                                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Unclear                                                    |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Who received LPV/r                                         |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Wan \[[35](#jia225489-bib-0035){ref-type="ref"}\]                                                     | 135 adult patients                                                                           | LPV/r (dose not reported)                                                                                                                                | All received interferon                                                                                                                                                                              | nr                                                                                        | n/a                                                    | LPV/r                                                      | Patient who died considered severe case                                                                                                                             |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          | Some received corticosteroids and traditional Chinese medicine                                                                                                                                       |                                                                                           |                                                        | 1/135                                                      |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Cai \[[36](#jia225489-bib-0036){ref-type="ref"}\]                                                     | 45 patients received LPV/r                                                                   | LPV/r 400/100 Q12H                                                                                                                                       | IFN‐α1b 60 μg twice daily                                                                                                                                                                            | 14 days                                                                                   | Favipiravir                                            | 0/45 died                                                  |                                                                                                                                                                     |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Comparative cohort study                                                                     |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Prevention                                                                                            |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Chen 2003 \[[38](#jia225489-bib-0038){ref-type="ref"}\]                                               | 19 patients Individuals with HIV (AIDS) infected with SARS                                   | 11/19 patients received ARVs: D4T/3TC/EFV = 3, d4T/3TC/NVP = 2, d4T/ddI/NVP = 3, Combivir/EFV = 1, Indinavir/EFV = 2                                     | Remaining 8 patients received treatment for opportunistic infections                                                                                                                                 | 15 patients stayed for \>1 month with SARS patients on the same floor.                    | n/a                                                    | LPV/r: 0/1 infected                                        | All 19 HIV patients (with AIDS) on the floor tested negative for SARS                                                                                               |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 | Retrospective cohort                                                                         |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Park 2019 \[[39](#jia225489-bib-0039){ref-type="ref"}\]                                               | 123 HCWs with unprotected exposure to a MERS‐CoV case of which 43 had a high‐risk exposure   | 22 received PEP and 21 were not given PEP; PEP protocol was RBV + LPV/r initiated between day 1 and day 3 after last unprotected exposure to the patient | 2 HCWs in the non‐PEP group wore masks, 3 HCWs wore gloves as personal protective equipment                                                                                                          | PEP given until day 14, initiated within 36 post exposure, median duration of PEP 12 days | Historical controls from 4 hospitals located far apart | LPV/r: 0/22 infected                                       | 6/43 had MERS‐CoV infection; Attack rate in PEP Vs non‐PEP groups: 0% Vs 28.6%, OR: 0.405 (0.274 to 0.599)                                                          |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| Rep Korea                                                                                             | Retrospective case control study                                                             |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        | Control: 6/21 infected                                     |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Guo 2020 \[[40](#jia225489-bib-0040){ref-type="ref"}\]                                                | 8 HIV positive individuals with COVID‐19 disease compared with 1166 without COVID‐19 disease | 947 patients received NNRTI‐ regimen                                                                                                                     | Use of protection measures unknown                                                                                                                                                                   | All antiretrovirals taken as HIV treatment                                                | HIV/AIDS patients in Wuchang and Qingshan district     | LPV/r:                                                     | Results not statistically significant                                                                                                                               |
|                                                                                                       |                                                                                              |                                                                                                                                                          |                                                                                                                                                                                                      |                                                                                           |                                                        |                                                            |                                                                                                                                                                     |
| China                                                                                                 |                                                                                              | 119 received LPV/r‐based regimen                                                                                                                         |                                                                                                                                                                                                      |                                                                                           |                                                        | 0/8 infected                                               |                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+--------------------------------------------------------+------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+

3TC, lamivudine; ARDS, acute respiratory distress syndrome; ATV/r, ritonavir‐boosted atazanavir; D4t, stavudine; ECMO, extracorporeal membrane oxygenation; HCWs, Healthcare workers; IFN, Interferon alpha; IU, international units; IV, intravenous; LPV/r, boosted lopinavir/ritonavir; MERS, middle‐east respiratory syndrome; MODS, multiple organ dysfunction syndrome; n/a, not applicable; nCoV, novel coronavirus; nr, not reported; NVP, nevirapine; peg‐IFN, pegylated interferon; PEP, post‐exposure prophylaxis; Q12H, twice daily; RBV, Ribavarin; SARS, Severe acute respiratory syndrome; SFJDC, ShuFengJieDu capsule; TDF, tenofovir.

Additional information provided by the authors.

John Wiley & Sons, Ltd

3.2. SARS {#jia225489-sec-0009}
---------

Two observational studies and one case report among patients with SARS \[[2](#jia225489-bib-0002){ref-type="ref"}, [17](#jia225489-bib-0017){ref-type="ref"}, [18](#jia225489-bib-0018){ref-type="ref"}\] reported outcomes of patients who were given antiretrovirals. A study from China reported a reduction in mortality in patients receiving LPV/r of 2.3% (95% CI 0% to 6.8%) compared to matched controls (15.6%, 9.8% to 22.8%) \[[2](#jia225489-bib-0002){ref-type="ref"}\]. A second study from China reported that none of the 41 patients given LPV/r died compared with seven of 111 patients in the control group \[[18](#jia225489-bib-0018){ref-type="ref"}\]. The third study, also from China, was a case report of a 30‐year‐old HIV‐positive man who recovered; he was receiving abacavir, efavirenz, tenofovir and LPV/r as antiretroviral therapy \[[17](#jia225489-bib-0017){ref-type="ref"}\]. All patients also received ribavirin and steroids of varying dose and duration.

3.3. MERS {#jia225489-sec-0010}
---------

Six observational studies, including two retrospective observational studies \[[3](#jia225489-bib-0003){ref-type="ref"}, [21](#jia225489-bib-0021){ref-type="ref"}\] and four case reports \[[16](#jia225489-bib-0016){ref-type="ref"}, [19](#jia225489-bib-0019){ref-type="ref"}, [20](#jia225489-bib-0020){ref-type="ref"}, [22](#jia225489-bib-0022){ref-type="ref"}\] -- one was from Greece, one from Austria, two from Saudi Arabia and two from the Republic of Korea -- provided data on patients diagnosed with MERS. There were 42 deaths among 165 patients who were given LPV/r together with other interventions including ribavirin and pegylated interferon.

3.4. COVID‐19 {#jia225489-sec-0011}
-------------

One randomized, controlled open‐label study reported on the efficacy and safety of LPV/r for treating hospitalized adults with severe COVID‐19 \[[23](#jia225489-bib-0023){ref-type="ref"}\]. In this trial 99 patients received LPV/r (400/100 mg twice a day; median time between symptom onset and randomization 13 days) and 100 patients received standard care for 14 days. LPV/r was not associated with a statistically significant difference in time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant in the intention‐to‐treat analysis. Accelerated clinical recovery and reduced mortality were observed in those treated within 12 days of symptom onset, but not in those treated later. Almost half of patients in the LPV/r group (46 patients, 48.4%) and control group (49 patients, 46.7%) reported one or more adverse events: gastrointestinal‐related complaints including nausea, vomiting and diarrhoea were more common in the lopinavir/ritonavir group. A second randomized trial assessed patients admitted to hospital with mild/moderate COVID‐19, and compared outcomes of 21 patients given LPV/r (200mg/50mg twice a day) with 16 patients given ardibol and 7 patients who were not given any antiviral therapy \[[24](#jia225489-bib-0024){ref-type="ref"}\]. In this trial, LPV/r did not show any benefit in terms of time to viral clearance (PCR negativity) or progression to severe disease. For both trials, certainty of the evidence was low due to risk of bias (investigators not blinded to the intervention, and imprecision.

In the observational studies, three case reports \[[25](#jia225489-bib-0025){ref-type="ref"}, [26](#jia225489-bib-0026){ref-type="ref"}, [27](#jia225489-bib-0027){ref-type="ref"}\]. three case series \[[28](#jia225489-bib-0028){ref-type="ref"}, [29](#jia225489-bib-0029){ref-type="ref"}, [30](#jia225489-bib-0030){ref-type="ref"}\], and six observational studies \[[31](#jia225489-bib-0031){ref-type="ref"}, [32](#jia225489-bib-0032){ref-type="ref"}, [33](#jia225489-bib-0033){ref-type="ref"}, [34](#jia225489-bib-0034){ref-type="ref"}, [35](#jia225489-bib-0035){ref-type="ref"}, [36](#jia225489-bib-0036){ref-type="ref"}\] reported outcomes of patients with COVID‐19 who received LPV/r; nine studies were from China, one was from Singapore and two from the Republic of Korea. Among the 361 patients in the nine studies where outcomes could be associated with receipt of LPV/r, three patients died. One study reported that 53 of 56 patients received LPV/r and three patients died; however, it was unclear how many of the patients who died had received LPV/r \[[31](#jia225489-bib-0031){ref-type="ref"}\].

LPV/r is recommended by WHO as part of second‐line antiretroviral therapy \[[37](#jia225489-bib-0037){ref-type="ref"}\]. Among people living with HIV receiving LPV/r diarrhoea, nausea and vomiting are commonly reported side effects at start of treatment \[[22](#jia225489-bib-0022){ref-type="ref"}\]. These side effects were reported by four out of five individuals who received LPV/r for the treatment of COVID‐19 in Singapore, and only one individual completed the 14‐day treatment course as a result of adverse events \[[29](#jia225489-bib-0029){ref-type="ref"}\].

The certainty of the evidence for outcomes across these three diseases is very low. The sample size was small and only two studies provided comparative outcomes (one using historical controls) and none used a randomized design to be able to assess the comparative effectiveness of different interventions. Timing, duration and dose of treatment varied, and in the majority of studies patients were provided with other interventions which may have contributed to the reported outcomes. GRADE Tables are provided in Appendix [S2](#jia225489-sup-0002){ref-type="supplementary-material"}.

3.5. Antiretroviral drugs as post‐exposure prophylaxis {#jia225489-sec-0012}
------------------------------------------------------

Three studies reported a possible protective effect of LPV/r against coronavirus infection \[[38](#jia225489-bib-0038){ref-type="ref"}, [39](#jia225489-bib-0039){ref-type="ref"}, [40](#jia225489-bib-0040){ref-type="ref"}\]. The first, a retrospective observational study from China, noted that 0 out of 19 patients hospitalized on same floor as SARS patients contracted the disease. Of the 19 patients, 11 were on differing regimens of antiretroviral therapy; none received LPV/r \[[38](#jia225489-bib-0038){ref-type="ref"}\]. The second study, from South Korea, retrospectively enrolled health care workers considered at high risk of MERS infection. Of 22 healthcare workers given post‐exposure prophylaxis (PEP) comprising ribavirin and LPV/r, none were infected; this compared to 9 of 21 healthcare workers not given PEP who became infected \[[39](#jia225489-bib-0039){ref-type="ref"}\]. The third study, from China, compared characteristics of 8 HIV‐positive individuals on different antiretroviral regimens who had contracted COVID‐19 infection with 1166 patients who had not been infected \[[40](#jia225489-bib-0040){ref-type="ref"}\]. No statistically significant relationship was found between type of antiretroviral regimen and infection status. The certainty of the evidence across outcomes was again very low due to uncertainty due to limited sample size, lack of uniformity of regimens being used to treat patients, and lack of information regarding intensity of exposure (Appendix [S2](#jia225489-sup-0002){ref-type="supplementary-material"}).

3.6. Registered clinical trials {#jia225489-sec-0013}
-------------------------------

Of 85 titles screened, 25 registered trials were identified that plan to assess the safety and efficacy of antiretrovirals -- 20 assessing LPV/r (including 1 for the treatment of MERS and one for SARS, the rest for COVID‐19), two ritonavir, two darunavir and cobicistat and one tenofovir alafenamide fumarate. Estimated completion dates are from March 2020 to January 2022 (Appendix [S3](#jia225489-sup-0003){ref-type="supplementary-material"}).

4. CONCLUSIONS {#jia225489-sec-0014}
==============

This systematic review identified two randomized trials and 21 observational studies provided clinical outcome data on the use of LPV/r for the treatment of COVID‐19, SARS and MERS. The randomized trials showed no clinical benefit, the observational studies were inconclusive, and the certainty of the body of evidence across all important outcomes was low or very low. Based on available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes in severe symptomatic disease or prevent infection among patients at high risk of acquiring COVID‐19. Any differences in potential therapeutic effect of LPV/r between SARS, MERS and COVID‐19 may partly be due to different clinical presentations; many of the patients had complicated courses including stays in intensive care units and were on multiple concurrent, unproven treatments.

Several randomized trials are planned to assess the safety and efficacy of antiretroviral drugs, including LPV/r, for the treatment of COVID‐19, MERS‐CoV and SARS‐CoV. While the conduct of such trials is challenging \[[41](#jia225489-bib-0041){ref-type="ref"}\], high quality evidence is needed to improve clinical and programmatic decisions to use antiretroviral drugs for current and future coronavirus outbreaks.

The procurement and use of LPV/r or other antiretroviral drugs to treat or prevent COVID‐19 infection should take into consideration the need to ensure continued availability for people living with HIV who need LPV/r as part of their antiretroviral therapy. Overuse of LPV/r for COVID‐19 in the current epidemic runs a risk of shortage of a drug that is currently used as a second line treatment for people living with HIV.

WHO plans to update this review at least monthly throughout 2020, and longer as needed, to update the evidence as new studies are completed.
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